Acidified nitrite - Arch Biopartners/University of Cincinnati

Drug Profile

Acidified nitrite - Arch Biopartners/University of Cincinnati

Alternative Names: A-NO2 - Arch Biopartners/University of Cincinnati; AB 569; ABP-569

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator University of Cincinnati
  • Class Anions; Antibacterials; Antihypertensives; Nitrites; Nitrogen compounds; Organic chemicals; Vasodilators
  • Mechanism of Action Bacterial growth modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pseudomonal infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pseudomonal infections
  • Preclinical Burkholderia cepacia infections; Staphylococcal infections

Most Recent Events

  • 03 Nov 2016 Arch Biopartners plans a phase I trial in chronic obstructive pulmonary disease
  • 01 Jun 2016 Acidified nitrite - Arch Biopartners/University of Cincinnati receives Orphan Drug status for Pseudomonal infections (in patients with Cystic fibrosis) in European Union
  • 26 Apr 2016 Arch Biopartners announces intention to submit an IND to US FDA in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top